title: Portal-enteric pancreas transplantation at the University of Tennessee, Memphis.
abstract: The UT Memphis group has made a number of important contributions to the field of PTX, including: 1) pioneering studies on the effects of PTX on autonomic neuropathy, 2) comprehensive reports dealing with quality of life after PTX, 3) seminal studies on the metabolic effects of PTX with portal venous delivery of insulin, 4) refining and perfecting a novel technique of PTX with portal venous drainage of insulin and primary enteric drainage of the exocrine secretions, 5) describing a safe outpatient percutaneous technique of pancreas allograft biopsy, 6) developing the use of glucose tolerance for rejection surveillance, and 7) managing PTX patients with biopsy-directed immunosuppression and no anti-lymphocyte induction therapy. The P-E technique has the potential to become the standard of care in the near future because it is more physiologic, normalizes carbohydrate and lipid metabolism, and minimizes complications attributed to the transplant procedure. In addition, we have been actively involved in studying new immunosuppressive regimens in order to improve and simplify the care of the PTX recipient. We believe that PTX will remain an important treatment option for IDDM until other strategies are developed that can provide equal glycemic control with less or no immunosuppression and less overall morbidity.
authors.affiliation: Departments of Surgery (Divison of Transplantation), Medicine, Nursing, and Pathology, University of Tennessee Memphis, Memphis, Tennessee, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: M H
authors.initials: MH
authors.lastname: Shokouh-Amiri
authors.forename: M F
authors.initials: MF
authors.lastname: Egidi
authors.forename: H P
authors.initials: HP
authors.lastname: Grewal
authors.forename: A T
authors.initials: AT
authors.lastname: Kizilisik
authors.forename: D K
authors.initials: DK
authors.lastname: Hathaway
authors.forename: L W
authors.initials: LW
authors.lastname: Gaber
authors.forename: A O
authors.initials: AO
authors.lastname: Gaber
mesh_terms: D000328:Adult; D002102:Cadaver; D000075202:Contraindications; D004322:Drainage / Q000379:methods; D005260:Female; D006085:Graft Survival; D006785:Hospitals, University; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000379:methods / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation; D016035:Pancreas Transplantation / Q000379:methods* / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data; D018579:Patient Selection; D011788:Quality of Life; D012307:Risk Factors; D015996:Survival Rate; D013714:Tennessee / Q000453:epidemiology; D014019:Tissue Donors; D009927:Tissue and Organ Procurement